Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assets

Formed by Sofinnova Partners and former Sanofi executive Frédéric Marrache, Bionyra Pharma emerged from stealth Monday with an initial focus in inflammatory bowel disease and atopic dermatitis.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top